A case report of neuromyelitis optica spectrum disorder induced by pembrolizumab treatment for lung adenocarcinoma: a clinical and immunohistochemical study

Shigeki Hirano,Akira Kojima,Yoko Nakayama,Takahiro Takeda,Takashi Kishimoto,Toshiyuki Takahashi,Satoshi Kuwabara,Masahiro Mori
DOI: https://doi.org/10.1186/s12883-022-02987-6
2022-12-16
BMC Neurology
Abstract:We report a case of neuromyelitis optica spectrum disorders (NMOSD), who developed after the pembrolizumab treatment, an immune checkpoint inhibitor, against lung adenocarcinoma. The present case is discussed with the lung adenocarcinoma specimen which was stained by aquaporin-4 (AQP4) and with literature review of NMOSD linked to immune checkpoint inhibitors.
clinical neurology
What problem does this paper attempt to address?